Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Oh, Byong Sun ^a   Jang, Jeong Won ^a,b   Kwon, Jung Hyun ^a   You, Chan Ran ^a   Chung, Kyu Won ^a   Kay, Chul Seung ^a   Jung, Hyun Suk ^a   Lee, Seungok ^a  

^a Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

C reactive protein; Hepatocellular carcinoma; Inflammation markers; Neutrophil to lymphocyte ratio; Survival

Indexed keywords

ALPHA FETOPROTEIN; C REACTIVE PROTEIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PATIENT CODING; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; SOUTH KOREA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KOREA; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873722551     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-78     Document Type: Article

References (33)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003, 362(9399):1907-1917.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236. 10.1002/hep.20933, 16250051.
3. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29(4):502-510. 10.1111/j.1478-3231.2008.01957.x, 2711257, 19141028.
4. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081. 10.1093/carcin/bgp127, 19468060.
5. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6(1):149-163. 10.2217/fon.09.136, 20021215.
6. Morris-Stiff G, Gomez D, Prasad KR. C-reactive protein in liver cancer surgery. Eur J Surg Oncol 2008, 34(7):727-729. 10.1016/j.ejso.2008.01.016, 18356004.
7. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103(9):1856-1864. 10.1002/cncr.20976, 15779015.
8. Lin ZY, Wang LY, Yu ML, Chen SC, Chuang WL, Hsieh MY, Tsai JF, Chang WY. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. J Gastroenterol Hepatol 2000, 15(4):417-421. 10.1046/j.1440-1746.2000.02149.x, 10824887.
9. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007, 27(8):1091-1097. 10.1111/j.1478-3231.2007.01550.x, 17845537.
10. Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 2012, 60(3):686-693. 10.1016/j.cyto.2012.07.017, 22906998.
11. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4(3):250-255. 10.1007/s11912-002-0023-1, 11937016.
12. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966, 123(2):365-378. 10.1084/jem.123.2.365, 2138142, 4379352.
13. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008, 19(2):353-358. 10.1093/annonc/mdm448, 17962206.
14. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 2012, 27(3):553-561. 10.1111/j.1440-1746.2011.06910.x, 21913982.
15. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008, 32(8):1757-1762. 10.1007/s00268-008-9552-6, 18340479.
16. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011, 22(5):702-709. 10.1016/j.jvir.2010.12.041, 21514523.
17. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009, 58(1):15-23. 10.1007/s00262-008-0516-3, 18414853.
18. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD. Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients. Ann Surg Oncol 2012, 19(1):217-224. 10.1245/s10434-011-1814-0, 21638095.
19. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010, 25(12):1427-1433. 10.1007/s00384-010-1052-0, 20821217.
20. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011, 104(5):504-510. 10.1002/jso.21986, 21618251.
21. Korean Liver Cancer Study Group and National Cancer Center K Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009, 15(3):391-423. Korean Liver Cancer Study Group and National Cancer Center K.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
23. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83(4):248-252. 10.1002/jso.10275, 12884238.
24. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92(4):651-654. 10.1038/sj.bjc.6602419, 2361875, 15700032.
25. Goldman ND, Liu TY. Biosynthesis of human C-reactive protein in cultured hepatoma cells is induced by a monocyte factor(s) other than interleukin-1. J Biol Chem 1987, 262(5):2363-2368.
26. Imai Y, Kubota Y, Yamamoto S, Tsuji K, Shimatani M, Shibatani N, Takamido S, Matsushita M, Okazaki K. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol 2005, 20(2):287-293. 10.1111/j.1440-1746.2004.03575.x, 15683434.
27. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011, 54(5):948-955. 10.1016/j.jhep.2010.08.041, 21145847.
28. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003, 6(4):283-287.
29. Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol 2011, 225(3):438-447. 10.1002/path.2947, 21826665.
30. McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P, Ferri LE. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 2009, 125(6):1298-1305. 10.1002/ijc.24409, 19431213.
31. Muller I, Munder M, Kropf P, Hansch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. Trends Immunol 2009, 30(11):522-530. 10.1016/j.it.2009.07.007, 19775938.
32. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007, 7:4. 2935759, 17311363.
33. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011, 91(11):1279-1285. 10.1097/TP.0b013e3182187cf0, 21617590.